Stock screenerAll disclosures →
EDGAR →
TVTX
Conviction 53HealthcareScan · Thu, Sep 24, 2026Travere Therapeutics, Inc. (TVTX) closed at $60.60 (+1.29%) on Sep 24, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 41, RS Rating 97, -10.3% from its 52-week high, +53.3% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.
TVTX$60.60+1.29%
ResistanceSupportVol 14Insider sell3
6
18
Vol MA14 1.69M
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Price60.60
Change+1.29%
Gap+0.05%
Rel volume1.36×
Avg volume1.53M
Avg $ vol97.74M
SMA 2064.65
SMA 5061.92
SMA 20044.27
Price vs 50-2.13%
Price vs 200+36.89%
MA stackmixed
50/200 cross—
Supertrenddown · 67.33
RSI (14)41
MACD hist-0.90
MACD cross—
Stoch %K / %D22 / 16
ADX (14)26
+DI / −DI15 / 29
RSI divergenceBearish
MACD divergenceBearish
ATR %4.10%
ADR %3.67%
52w high67.52
52w low23.90
From 52w high-10.25%
Above 52w low+153.56%
New 52w highNo
SqueezeOff
Bollinger width14.60%
%B0.07
Donchian pos21.90%
Donchian high68.73
Donchian low58.32
AVWAP (52w high)62.62
vs AVWAP high-3.23%
AVWAP (52w low)41.02
vs AVWAP low+47.72%
OBV trendFlat
Chaikin MF (20)-0.08
Today vs 20d1.36×
Avg vol (14d)1.69M
Avg vol (20d)1.53M
Avg $ vol (20d)97.74M
Market cap5.71B
RS Rating97 / 99
RS 3m (vs SPY)-1.83%
RS 6m (vs SPY)+103.07%
RS line new highNo
Trend template6/8
Technical rank71.6
1 week-6.39%
1 month-9.57%
3 months+2.66%
6 months+119.88%
1 year+150.10%
YTD+53.34%
P/E-223.61
P/B232.94
P/S11.64
P/FCF153.90
EPS-0.2900
Div yield—
ROE-104.18%
ROA-3.20%
Debt/Eq1.88
Current4.05
EV/EBITDA—
Gross margin—
Net margin-5.21%
Rev growth110.45%
EPS growth92.06%
Price target75.92
Target upside25.28%
Analyst ratingBuy
Institutional131.27%
Ent. value5.64B
Revenue169.58M
Net income-34.8M
Gross profit—
Free cash flow37.12M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out92.99M
Employees497
ListedWed, Jul 23, 2003
Free float90.39M
Float %98.0%
Short interest12M
Days to cover9.6d
Short volume36.0%
Squeeze score57 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.37 vs −$0.14
Last surprise-164.3% miss
Setup gradeC
Conviction53 / 100
Pattern quality—
Tech rank71.6 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance68.38
Support56.81
Days since event—
Candle confirm—
Financials as of Tue, Jun 30, 2026 · quarterly.
Recent news
- Travere Therapeutics, Inc.: Management changeSEC EDGAR · Mon, Sep 21, 2026
Congress activity
Disclosed STOCK Act trades in TVTX
No recent disclosed trades by Congress in TVTX. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in TVTX · open-market 3 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Dube Eric M CHIEF EXECUTIVE OFFICER · Common Stock · 2026-09-17 | Exercise | 108.49K | $2.5M | 2026-09-17 | 2026-09-17 |
Dube Eric M CHIEF EXECUTIVE OFFICER · Common Stock · 2026-09-17 | Sell | 101.69K | $6.6M | 2026-09-17 | 2026-09-17 |
Heerma Peter EVP, CHIEF COMMERCIAL OFFICER · Common Stock · 2026-09-17 | Exercise | 8.28K | $186K | 2026-09-17 | 2026-09-17 |
Heerma Peter EVP, CHIEF COMMERCIAL OFFICER · Common Stock · 2026-09-17 | Sell | 8.28K | $539K | 2026-09-17 | 2026-09-17 |
Heerma Peter EVP, CHIEF COMMERCIAL OFFICER · Employee stock option (right to buy) · 2026-09-17 | Exercise | 8.28K | — | 2026-09-17 | 2026-09-17 |
Dube Eric M CHIEF EXECUTIVE OFFICER · Employee stock option (right to buy) · 2026-09-17 | Exercise | 108.49K | — | 2026-09-17 | 2026-09-17 |
Dube Eric M CHIEF EXECUTIVE OFFICER · Common Stock · 2026-09-17 | Sell | 6.8K | $442K | 2026-09-17 | 2026-09-17 |
Heerma Peter EVP, CHIEF COMMERCIAL OFFICER · Common Stock · 2026-09-16 | Exercise | 100K | $1.1M | 2026-09-16 | 2026-09-17 |
Heerma Peter EVP, CHIEF COMMERCIAL OFFICER · Common Stock · 2026-09-16 | Exercise | 55K | $850K | 2026-09-16 | 2026-09-17 |
Heerma Peter EVP, CHIEF COMMERCIAL OFFICER · Common Stock · 2026-09-16 | Exercise | 17.72K | $476K | 2026-09-16 | 2026-09-17 |
SEC filings
EDGAR filings in TVTX · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.